Cargando…

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy

BACKGROUND: We assessed the sensitivity to adjuvant chemotherapy in cell cycle checkpoint kinase 2 (CHEK2) vs non-CHEK2 breast cancer patients by comparing the contralateral breast cancer incidence and distant disease-free and breast cancer-specific survival between both groups, stratified for adjuv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kriege, M, Hollestelle, A, Jager, A, Huijts, P E A, Berns, E M, Sieuwerts, A M, Meijer-van Gelder, M E, Collée, J M, Devilee, P, Hooning, M J, Martens, J W M, Seynaeve, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150261/ https://www.ncbi.nlm.nih.gov/pubmed/24918820 http://dx.doi.org/10.1038/bjc.2014.306

Ejemplares similares

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers
por: Kriege, Mieke, et al.
Publicado: (2015)

Risk for contralateral breast cancer among carriers of the CHEK2(*)1100delC mutation in the WECARE Study
por: Mellemkjær, L, et al.
Publicado: (2008)

Genetic modifiers of CHEK2*1100delC associated breast cancer risk
por: Muranen, Taru A., et al.
Publicado: (2016)

Genomic profiling of CHEK2*1100delC-mutated breast carcinomas
por: Massink, Maarten P. G., et al.
Publicado: (2015)

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival
por: Morra, Anna, et al.
Publicado: (2023)

CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum
por: Isinger, Anna, et al.
Publicado: (2006)

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
por: Morra, Anna, et al.
Publicado: (2023)

A Case of Male Breast Cancer Patient with CHEK2*1100delC Mutation
por: Nguyen, Quan D, et al.
Publicado: (2020)

Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile
por: Smid, Marcel, et al.
Publicado: (2023)

Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer
por: Woodward, Emma R., et al.
Publicado: (2021)

CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer
por: Margolin, Sara, et al.
Publicado: (2007)

Frequency of CHEK2*1100delC in New York breast cancer cases and controls
por: Offit, Kenneth, et al.
Publicado: (2003)

CHEK2 (∗)1100delC Mutation and Risk of Prostate Cancer
por: Hale, Victoria, et al.
Publicado: (2014)

The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis
por: Koppert, L B, et al.
Publicado: (2004)

CHEK2 1100 delC mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2007)

Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications
por: Muranen, Taru A, et al.
Publicado: (2011)

A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients
por: Wendt, Camilla, et al.
Publicado: (2021)

Frequency of the CHEK2 1100delC mutation among women with early-onset and bilateral breast cancer
por: Ding, Dapeng, et al.
Publicado: (2012)

Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families
por: Cierniková, S, et al.
Publicado: (2005)

Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals
por: Jekimovs, C R, et al.
Publicado: (2005)

CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population
por: Hallamies, Sanna, et al.
Publicado: (2017)

The CHEK2 1100delC allelic variant is not present in familial and sporadic breast cancer cases from Moroccan population
por: Marouf, Chaymaa, et al.
Publicado: (2015)

BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
por: Francies, F. Z., et al.
Publicado: (2015)

Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma
por: Thibodeau, My Linh, et al.
Publicado: (2017)

Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk
por: Varley, Jenny, et al.
Publicado: (2003)

Corrigendum: Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma
por: Thibodeau, My Linh, et al.
Publicado: (2018)

Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences
por: Velthuizen, Mary E., et al.
Publicado: (2021)

Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
por: Verhoog, L C, et al.
Publicado: (2000)

Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study
por: Wevers, M. R., et al.
Publicado: (2015)

CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II
por: Lopez, Santiago J., et al.
Publicado: (2023)

The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer
por: Liu, Jingjing, et al.
Publicado: (2016)

Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age
por: Drooger, Jan C., et al.
Publicado: (2015)

The checkpointkinase 2 (CHK2) 1100delC germ line mutation is not associated with the development of squamous cell carcinoma of the head and neck (SCCHN)
por: Scheckenbach, Kathrin, et al.
Publicado: (2010)

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer
por: Lammers, L A, et al.
Publicado: (2010)

Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer
por: Giardiello, Daniele, et al.
Publicado: (2020)

MUTYH gene variants and breast cancer in a Dutch case–control study
por: Out, Astrid A., et al.
Publicado: (2012)

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study
por: Akdeniz, Delal, et al.
Publicado: (2021)

CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer
por: van Agthoven, T, et al.
Publicado: (2009)

Prediction and clinical utility of a contralateral breast cancer risk model
por: Giardiello, Daniele, et al.
Publicado: (2019)

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
por: van Sprundel, T C, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_n5dtq2sl02t01b1fd1asv03u4m